Healthcare / BiotechnologyNasdaqGS
$4.24
-0.11 (-2.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-76.8M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1198.6%
↓Gross Margin
50.2%
↑Debt/Equity
4.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
—
FCF margin
-927.6%
FCF / Net income
0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.7M · net income $-250.6M · FCF $-89.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $9.7M | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M | $32.0M | $90.7M | $151.2M | $219.5M | $190.9M | $173.6M | $71.9M | $23.8M | $13.8M | $8.0M |
| Net Income | $-250.6M | $-250.6M | $-126.2M | $-95.9M | $28.3M | $-92.2M | $-170.5M | $-322.3M | $-509.3M | $-117.0M | $-186.6M | $-84.5M | $-81.8M | $-39.0M | $-81.9M | $-85.3M |
| EBITDA | $-243.6M | $-243.6M | $-123.5M | $-89.2M | $-62.4M | — | — | — | $-472.5M | $-106.7M | $-100.6M | $-129.1M | $-59.5M | $-50.8M | $-67.2M | $-78.1M |
| EPS | -1.37 | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | — | — | — | — | — | — | — | — |
| Gross Margin | 50.2% | 50.2% | -8.7% | 1.7% | 76.4% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1100.8% | -1100.8% | -2412.9% | -1428.5% | -277.3% | — | — | — | -334.4% | -62.8% | -65.6% | -84.6% | -97.3% | -244.2% | -545.6% | -1028.7% |
| Net Margin | -2588.2% | -2588.2% | -3216.2% | -1540.6% | 105.2% | -646.0% | -533.0% | -355.3% | -336.9% | -53.3% | -97.7% | -48.7% | -113.8% | -164.1% | -594.4% | -1064.3% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 4.70 | 4.70 | 0.14 | 0.06 | 0.41 | 1.68 | 2.55 | 2.60 | 0.58 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | — | — |
| Current Ratio | 4.82 | 4.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-89.8M | $-89.8M | $-76.8M | $-68.5M | $-70.0M | $-63.0M | $-84.5M | $-173.8M | $-165.8M | $-150.4M | $-80.6M | $22.9M | $-26.2M | $-55.2M | $-69.0M | $-94.8M |
| Returns | ||||||||||||||||
| ROE | -1198.6% | -1198.6% | -327.8% | -80.9% | 22.4% | -85.9% | -253.8% | -449.5% | -140.4% | -21.9% | -33.3% | -12.2% | -21.3% | -10.6% | 25.5% | — |
| Valuation | ||||||||||||||||
| P/E | — | — | — | — | 11.43 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 63.39 | 63.39 | 8.34 | 2.66 | 2.54 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 146.7% | 146.7% | -36.9% | -76.9% | — | -55.4% | -64.7% | -40.0% | -31.1% | 14.9% | 10.0% | 141.4% | 202.7% | 72.5% | 71.9% | — |
| EPS Growth | -191.5% | -191.5% | -20.5% | -378.6% | — | 53.9% | 51.2% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+220.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.47 → -1.37
Residual
+220.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.